Literature DB >> 15964750

Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.

J I Gregor1, M Kilian, I Heukamp, C Kiewert, G Kristiansen, I Schimke, M K Walz, C A Jacobi, F A Wenger.   

Abstract

Selective inhibition of eicosanoid synthesis seems to decrease carcinogenesis, however, the effect on liver metastasis in pancreatic cancer is still unknown. Ductal pancreatic adenocarcinoma was chemically induced by weekly injection of N-nitrosobis-2-oxopropylamine (BOP) in Syrian hamster. Animals received selective inhibition of cyclooxygenase-2 (Celebrex) and 5-lipoxygenase (Zyflo). In week 33, hamsters were sacrificed and incidence of pancreatic carcinomas as well as liver metastases were examined. Furthermore, size and number of liver metastases per animal were determined and concentration of PGF1alpha, PGE2 and leukotrienes was measured in hepatic and pancreatic tissue. Combined therapy (Celebrex+Zyflo) significantly decreased incidence, number and size of liver metastases. Furthermore extra- and intrametastatic concentration of PGE2 was reduced by this treatment in hepatic tissue. Single Cox-2-inhibition (Celebrex) decreased intrametastatic hepatic PGF1alpha and PGE2 concentration while PGF1alpha concentration was reduced in non-metastatic liver (nml). Moreover 5-LOX-inhibition (Zyflo) decreased intrametastatic PGE2 concentration as well as PGF1alpha and PGE2 in nml. In pancreatic carcinomas highest LT-concentration was found after combined treatment and this therapy group was the only one revealing a significantly higher amount of LTs in carcinomas compared to tumour-free tissue. Hepatic LT-concentration was significantly lower in the control groups than in nml of the tumour groups. Combination of Cox-2-inhibition and 5-Lox-inhibition might be a suitable adjuvant therapy to prevent liver metastasis in human ductal pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964750     DOI: 10.1016/j.plefa.2005.04.016

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  7 in total

1.  Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.

Authors:  Hiroki Takahashi; Aihua Li; David W Dawson; Oscar Joe Hines; Howard A Reber; Guido Eibl
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

2.  The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.

Authors:  A Rossi; C Pergola; A Koeberle; M Hoffmann; F Dehm; P Bramanti; S Cuzzocrea; O Werz; L Sautebin
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2.

Authors:  Bo Zhang; Chang-Liang Wang; Wen-Hua Zhao; Ming Lv; Chun-Ying Wang; Wei-Xia Zhong; Wu-Yuan Zhou; Wen-Sheng Yu; Yan Zhang; Sheng Li
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

4.  Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction.

Authors:  Leyla Abueid; Ünal Uslu; Alev Cumbul; Ayliz Velioğlu Öğünç; Feriha Ercan; İnci Alican
Journal:  Anatol J Cardiol       Date:  2016-11-10       Impact factor: 1.596

5.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

Review 6.  Multiple roles of dihomo-γ-linolenic acid against proliferation diseases.

Authors:  Xiaoping Wang; Huanping Lin; Yan Gu
Journal:  Lipids Health Dis       Date:  2012-02-14       Impact factor: 3.876

7.  A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.

Authors:  Ning Ding; Xiao-Xing Cui; Zhi Gao; Huarong Huang; Xingchuan Wei; Zhiyun Du; Yong Lin; Weichung Joe Shih; Arnold B Rabson; Allan H Conney; Chunhong Hu; Xi Zheng
Journal:  Int J Oncol       Date:  2014-03-19       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.